Investing.com -- Cognition Therapeutics Inc (NASDAQ: CGTX) stock surged 14% following the announcement of upcoming presentations of Phase 2 study results for its dementia with Lewy bodies (DLB) ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...